Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 32Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Neoplasm Metastasis 3Carcinoma, Ovarian Epithelial 3Pancreatic Neoplasms 2Lung Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Sarcoma 1Recurrent Uterine Corpus Sarcoma 1Recurrence 1Pain 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Liver Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Endometrial Adenocarcinoma 1

Interventions

Rituximab 134Cyclophosphamide 100Vincristine 53fludarabine phosphate 50Prednisone 50Doxorubicin 49Etoposide 47Peripheral Blood Stem Cell Transplantation 38Mycophenolic Acid 37Whole-Body Irradiation 35Tacrolimus 29Busulfan 27Lenalidomide 26Filgrastim 26Cyclosporine 26Melphalan 24Methotrexate 21Antilymphocyte Serum 21Gemcitabine 18ibritumomab tiuxetan 17Granulocyte Colony-Stimulating Factor 17Cytarabine 17Carmustine 16Radiotherapy 15fludarabine 14Carboplatin 14Bendamustine Hydrochloride 14pembrolizumab 13ibrutinib 12Sirolimus 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large B-Cell, Diffuse × ixabepilone × Clear all
NCT00058019 2014-05-23

Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
51 enrolled 14 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡